Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label single-arm study of inhaled nitric oxide with ventilatory support in near-term and term neonates with hypoxic respiratory failure and pulmonary hypertension
CTR20243016Phase 4Active
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nitric oxide in hypoxemic respiratory failure, pulmonary hypertension (PH), sponsored by Mallinckrodt Pharmaceuticals. Started Dec 2024; status: active.
02
Drugs
nitric oxide
03
Conditions
hypoxemic respiratory failurepulmonary hypertension (PH)
Beyond the preview
Go deeper on CTR20243016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243016.